A potently neutralizing and protective human antibody targeting antigenic site V on RSV and hMPV fusion glycoprotein.
Summary
Using LIBRA-seq, the authors discovered a human monoclonal antibody (RM 5-1) that cross-neutralizes diverse RSV and hMPV strains and protects mice in challenge models. Structural work shows RM 5-1 targets an epitope spanning sites Ø, II, and V on the F protein, providing a blueprint for broad antiviral design.
Key Findings
- Identified five RSV/hMPV cross-reactive human antibodies via LIBRA-seq.
- RM 5-1 potently neutralized all tested subgroups of RSV and hMPV and protected mice in challenge models.
- Structural studies revealed RM 5-1 binds an epitope spanning sites Ø, II, and V with an uncommon genetic signature.
Clinical Implications
Supports development of a universal monoclonal for RSV/hMPV prophylaxis or treatment and informs vaccine immunogen design focusing on conserved F-protein epitopes.
Why It Matters
Demonstrates a single antibody with broad, cross-family neutralization and in vivo protection against two major respiratory viruses, advancing prophylactic and therapeutic strategies.
Limitations
- Preclinical study without human clinical efficacy data.
- Breadth against future antigenic drift and potential escape not fully established.
Future Directions
Advance RM 5-1 to IND-enabling studies (PK/PD, safety, Fc engineering), map escape pathways, and evaluate combination strategies or long-acting prophylaxis in high-risk populations.
Study Information
- Study Type
- Case-control
- Research Domain
- Treatment
- Evidence Level
- V - Preclinical mechanistic and in vivo mouse protection data without human trials.
- Study Design
- OTHER